by Micah Harman | Oct 31, 2024 | Press Releases, Interviews/Speaking/Events
LEHI, Utah, October 31, 2024 /PRNewswire/—Halia Therapeutics, Inc. (Halia), a clinical-stage biopharmaceutical company pioneering innovative treatments for chronic inflammatory diseases, announced today that it will present promising data on HT-6184’s potential... by Micah Harman | Oct 16, 2024 | Interviews/Speaking/Events, News & Media
BIO News BIF 2024: What’s happening with neurodegenerative disease targets and pipelines? BIF 2024: What’s happening with neurodegenerative disease targets and pipelines? Clary Estes October 15, 2024 There is a great degree of renewed optimism for drug... by Micah Harman | Oct 14, 2024 | Press Releases, Interviews/Speaking/Events
Dr. David J. Bearss, CEO, will partake in a panel focused on Neurodegenerative Disease Targets and Pipelines on Tuesday, October 15 at 11:00-11:50 am PT LEHI, Utah, Oct. 14, 2024 /PRNewswire/ — Halia Therapeutics, Inc. (Halia), a clinical-stage... by Halia Therapeutics | Oct 4, 2024 | News & Media, Interviews/Speaking/Events
Listen to Dr David Bearss discuss Halia’s work on Alzheimer’s and other inflammation-related diseases https://podcasts.apple.com/us/podcast/dr-dave-bearss-co-founder-ceo-of-halia-on-pioneering/id1482108463?i=1000671780322 Explore the forefront of biotech... by Halia Therapeutics | Sep 3, 2024 | News & Media, Interviews/Speaking/Events
For decades drugmakers have taken a more-is-more model when dosing cancer drugs in clinical trials. U.S. regulators want them to reconsider that approach. Companies with cancer drugs in clinical trials must strike a balance between doses high enough to thwart...